Chinese Biotechs Make Breakthroughs in Multiple System Atrophy with Novel Cell Therapies

　　【Pharmaceutical Network Industry Dynamics】Multiple System Atrophy (MSA) is a rapidly progressing adult neurodegenerative disease, with most patients facing life-threatening conditions within 6 to 10 years after diagnosis, creating an urgent demand in the pharmaceutical market. It is reported that, in response to this disease area, pharmaceutical companies in China are increasingly focusing on the development of innovative drugs and have achieved new progress.
 

Recently, XsellSmart announced that its self-developed allogeneic "off-the-shelf" iPSC-derived subtype neural cell new drug has received full approval from the National Medical Products Administration (NMPA) without any requests for supplementary information. The drug will proceed to Phase I/II clinical trials for the treatment of the fatal neurodegenerative rare disease — Parkinsonian-type Multiple System Atrophy. This progress marks that, following treatments for Parkinson's disease, spinal cord injury, and ALS, XsellSmart is further promoting its self-developed universal clinical iPSC regenerative cell therapy solutions, continuously deepening and expanding in the field of highly unmet clinical needs for neurodegenerative diseases.
 

It is reported that XsellSmart has adopted its self-developed allogeneic "off-the-shelf" iPSC-derived subtype neural cell regeneration to treat Parkinsonian multiple system atrophy (MSA), providing an innovative treatment solution for this "incurable" neurodegenerative rare disease through regenerative dopamine secretion and promotion of circuit and brain environment repair. This marks a significant clinical exploration in the global field of neurodegenerative disease treatment, with the potential to offer patients worldwide a new therapeutic option and hope. The pathological core of MSA lies in the abnormal aggregation of α-synuclein in oligodendrocytes, leading to myelin damage and nerve conduction disorders, which progressively destroy several key brain regions.
 

The progress of XsellSmart is not an isolated case; pharmaceutical companies in China are forming a favorable situation of multi-point breakthroughs. According to the review, in addition to XsellSmart, in October 2025, iRegene also announced that its self-developed NouvNeu004 injection has officially received approval from the National Medical Products Administration for Phase I-III full-cycle clinical trial applications. This marks the formal entry into the clinical stage of a cell therapy product targeting multiple system atrophy. NouvNeu004 adopts an innovative "neuro-nutrition + neuro-reconstruction" composite treatment strategy. On one hand, it provides nutritional support to endangered cells in lesion areas, preventing their further death; on the other hand, it induces differentiation into nerve cells through micro-environmental induction at multiple lesion sites, achieving systemic neural repair and functional reconstruction.
 

NOVABIOTX's self-developed "Human Autologous Polyclonal Regulatory T Cell Injection" was also approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in December 2025, officially launching clinical trials for Multiple System Atrophy (MSA). It is reported that the approved clinical trial for MSA (application number: CXSL2500817) will comprehensively cover the two major subtypes of MSA, systematically evaluating the safety, tolerability, and preliminary efficacy of the Treg cell injection (NP001).
 

Data shows that Multiple System Atrophy (MSA), as a rare disease with highly unmet clinical needs, brings tremendous suffering to patients and their families. MSA is a fatal and progressive neurodegenerative disease. Patients typically present with a combination of autonomic dysfunction, parkinsonism, and cerebellar ataxia. The condition is complex, extremely challenging to diagnose and treat, progresses rapidly, and most patients face life-threatening risks within 6 to 10 years after diagnosis.
 

Continuous breakthroughs in innovative drugs are expected to bring new hope to patients with multiple system atrophy (MSA). However, the significant progress made by pharmaceutical companies in China in the MSA field is also inseparable from the policy support for rare disease innovative drugs. In recent years, China has continued to deepen the reform of drug regulation, establishing "green channels" for urgently needed rare disease drugs through measures such as priority review and approval, optimizing clinical trial requirements, and reducing registration inspection costs. Data shows that the average review time for new drug marketing applications in China in 2024 has been shortened to 225 working days, while priority review products have been reduced to as low as 162 working days. The policy dividend is accelerating the transformation into "drug accessibility" for patients. As clinical trials by XsellSmart and iRegene gradually progress, there is anticipation that these innovative therapies will soon be implemented, dispelling the gloom for MSA patients worldwide.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.